EichorEICHOR
Condition: Msi H Solid Malignant Tumor Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Msi H Solid Malignant Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Phase 1/Phase 2 · 22 location(s) · Nimbus Wadjet, Inc. · NCT06898450A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Phase 2 · 1 location(s) · University Medical Center Groningen · NCT05483400Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Phase 2 · 1 location(s) · Dan Zandberg · NCT04114136Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 15 location(s) · MOMA Therapeutics · NCT06974110Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Phase 2 · 10 location(s) · Peking University · NCT07127822Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Phase N/A · 8 location(s) · Elephas · NCT07327489Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT03810339Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Phase 2 · 1 location(s) · Peking University · NCT06580574
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.